We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Noncontact transscleral Nd:YAG cyclophotocoagulation for glaucoma after penetrating keratoplasty.
American Journal of Ophthalmology 1995 November
PURPOSE: To evaluate the effect of noncontact transscleral Nd:YAG cyclophotocoagulation for refractory glaucoma after penetrating keratoplasty on intraocular pressure, visual acuity, and graft status.
METHODS: We reviewed the records of all patients treated at the Duke University Eye Center between 1988 and 1993 who had noncontact transscleral Nd:YAG cyclophotocoagulation for uncontrolled glaucoma associated with penetrating keratoplasty.
RESULTS: One eye each of 39 patients was included in the study. At final follow-up, ranging from three to 63 months (mean, 27 +/- 18 months), the average decrease in intraocular pressure was 15 mm Hg (P = .001). Thirty-one patients (77%) had a final intraocular pressure between 7 and 21 mm Hg. The number of medications was reduced by an average of 1.4 (P = .0001). Five patients (13%) showed an improvement in best-corrected visual acuity at final follow-up; 12 (31%) maintained stable acuity, and 22 (56%) demonstrated a- deterioration in acuity. Of 25 patients with clear grafts before cyclophotocoagulation, 11 (44%) had graft decompensation.
CONCLUSIONS: Noncontact transscleral Nd:YAG cyclophotocoagulation is effective in lowering intraocular pressure in eyes with refractory glaucoma and associated penetrating keratoplasty, although loss of visual acuity and graft decompensation remain important concerns. Further study is needed of other cyclophotocoagulation protocols and alternative treatments for this patient population.
METHODS: We reviewed the records of all patients treated at the Duke University Eye Center between 1988 and 1993 who had noncontact transscleral Nd:YAG cyclophotocoagulation for uncontrolled glaucoma associated with penetrating keratoplasty.
RESULTS: One eye each of 39 patients was included in the study. At final follow-up, ranging from three to 63 months (mean, 27 +/- 18 months), the average decrease in intraocular pressure was 15 mm Hg (P = .001). Thirty-one patients (77%) had a final intraocular pressure between 7 and 21 mm Hg. The number of medications was reduced by an average of 1.4 (P = .0001). Five patients (13%) showed an improvement in best-corrected visual acuity at final follow-up; 12 (31%) maintained stable acuity, and 22 (56%) demonstrated a- deterioration in acuity. Of 25 patients with clear grafts before cyclophotocoagulation, 11 (44%) had graft decompensation.
CONCLUSIONS: Noncontact transscleral Nd:YAG cyclophotocoagulation is effective in lowering intraocular pressure in eyes with refractory glaucoma and associated penetrating keratoplasty, although loss of visual acuity and graft decompensation remain important concerns. Further study is needed of other cyclophotocoagulation protocols and alternative treatments for this patient population.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app